Suppr超能文献

胆固醇结合化合物两性霉素B甲酯对1型人类免疫缺陷病毒组装和释放的抑制作用：Vpu依赖性的证据

Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence.

作者信息

Waheed Abdul A, Ablan Sherimay D, Soheilian Ferri, Nagashima Kunio, Ono Akira, Schaffner Carl P, Freed Eric O

机构信息

Virus-Cell Interaction Section, HIV Drug Resistance Program, NCI-Frederick, Bldg. 535, Rm. 108, Frederick, MD 21702-1201, USA.

出版信息

J Virol. 2008 Oct;82(19):9776-81. doi: 10.1128/JVI.00917-08. Epub 2008 Jul 23.

DOI:10.1128/JVI.00917-08
PMID:18653459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2546975/
Abstract

We investigated the mechanism by which the cholesterol-binding compound amphotericin B methyl ester (AME) inhibits human immunodeficiency virus type 1 (HIV-1) particle production. We observed no significant effect of AME on Gag binding to the plasma membrane, Gag association with lipid rafts, or Gag multimerization, indicating that the mechanism of inhibition by AME is distinct from that by cholesterol depletion. Electron microscopy analysis indicated that AME significantly disrupts virion morphology. Interestingly, we found that AME does not inhibit the release of Vpu-defective HIV-1 or Vpu(-) retroviruses such as murine leukemia virus and simian immunodeficiency virus. We demonstrated that the ability of Vpu to counter the activity of CD317/BST-2/tetherin is markedly reduced by AME. These results indicate that AME interferes with the anti-CD317/BST-2/tetherin function of Vpu.

摘要

我们研究了胆固醇结合化合物两性霉素B甲酯（AME）抑制1型人类免疫缺陷病毒（HIV-1）颗粒产生的机制。我们观察到AME对Gag与质膜的结合、Gag与脂筏的缔合或Gag多聚化均无显著影响，这表明AME的抑制机制与胆固醇耗竭的机制不同。电子显微镜分析表明，AME显著破坏病毒体形态。有趣的是，我们发现AME并不抑制Vpu缺陷型HIV-1或Vpu（-）逆转录病毒（如鼠白血病病毒和猴免疫缺陷病毒）的释放。我们证明，AME可显著降低Vpu对抗CD317/BST-2/栓系蛋白活性的能力。这些结果表明，AME干扰了Vpu的抗CD317/BST-2/栓系蛋白功能。

相似文献

1
Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence.
J Virol. 2008 Oct;82(19):9776-81. doi: 10.1128/JVI.00917-08. Epub 2008 Jul 23.
2
Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
PLoS One. 2013 Sep 24;8(9):e75680. doi: 10.1371/journal.pone.0075680. eCollection 2013.
3
HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
J Virol. 2016 Jul 11;90(15):6709-6723. doi: 10.1128/JVI.00504-16. Print 2016 Aug 1.
4
The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.02315-18. Print 2019 Jun 1.
5
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
Nature. 2008 Jan 24;451(7177):425-30. doi: 10.1038/nature06553. Epub 2008 Jan 16.
6
Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
J Virol. 2020 Jan 6;94(2). doi: 10.1128/JVI.01669-19.
7
HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
Virology. 2012 Mar 1;424(1):33-44. doi: 10.1016/j.virol.2011.12.008. Epub 2012 Jan 4.
8
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
J Virol. 2009 Aug;83(15):7536-46. doi: 10.1128/JVI.00620-09. Epub 2009 May 27.
9
β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Retrovirology. 2011 Feb 10;8:9. doi: 10.1186/1742-4690-8-9.
10
Vpu binds directly to tetherin and displaces it from nascent virions.
PLoS Pathog. 2013;9(4):e1003299. doi: 10.1371/journal.ppat.1003299. Epub 2013 Apr 25.

引用本文的文献

1
Interferon-Induced Transmembrane Protein 3 (IFITM3) Restricts PRRSV Replication via Post-Entry Mechanisms.
Microorganisms. 2025 Jul 25;13(8):1737. doi: 10.3390/microorganisms13081737.
2
Neutral sphingomyelinase 2 is required for HIV-1 maturation.
Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2219475120. doi: 10.1073/pnas.2219475120. Epub 2023 Jul 5.
3
Analysis of HIV-1 envelope cytoplasmic tail effects on viral replication.
Virology. 2023 Feb;579:54-66. doi: 10.1016/j.virol.2022.12.017. Epub 2023 Jan 2.
4
Antifungal Macrocycle Antibiotic Amphotericin B-Its Present and Future. Multidisciplinary Perspective for the Use in the Medical Practice.
Biochem Mosc Suppl B Biomed Chem. 2022;16(1):1-12. doi: 10.1134/S1990750822010024. Epub 2022 Feb 14.
5
Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV-1 Env Clustering.
Adv Sci (Weinh). 2020 Dec 21;8(3):2003468. doi: 10.1002/advs.202003468. eCollection 2021 Feb.
6
LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
J Virol. 2020 Aug 31;94(18). doi: 10.1128/JVI.00562-20.
7
Potent and Selective Activity against Human Immunodeficiency Virus 1 (HIV-1) of Extracts.
Viruses. 2020 Jun 19;12(6):664. doi: 10.3390/v12060664.
8
Insights into HIV-1 Vpu-Tetherin Interactions and Its Mutational Counterparts.
Med Sci (Basel). 2019 Jun 22;7(6):74. doi: 10.3390/medsci7060074.
9
Amphotericin B Inhibits Enterovirus 71 Replication by Impeding Viral Entry.
Sci Rep. 2016 Sep 9;6:33150. doi: 10.1038/srep33150.
10
Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein.
J Mol Biol. 2016 Apr 24;428(8):1637-55. doi: 10.1016/j.jmb.2016.03.005. Epub 2016 Mar 16.

本文引用的文献

1
The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
Cell Host Microbe. 2008 Apr 17;3(4):245-52. doi: 10.1016/j.chom.2008.03.001. Epub 2008 Mar 13.
2
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
Nature. 2008 Jan 24;451(7177):425-30. doi: 10.1038/nature06553. Epub 2008 Jan 16.
3
Modulation of the severe CD4+ T-cell loss caused by a pathogenic simian-human immunodeficiency virus by replacement of the subtype B vpu with the vpu from a subtype C HIV-1 clinical isolate.
Virology. 2008 Feb 5;371(1):86-97. doi: 10.1016/j.virol.2007.09.015. Epub 2007 Oct 24.
4
HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8467-71. doi: 10.1073/pnas.0701443104. Epub 2007 May 4.
5
Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag.
Virology. 2007 Mar 30;360(1):27-35. doi: 10.1016/j.virol.2006.10.011. Epub 2006 Nov 13.
6
Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants.
J Biol Chem. 2006 Sep 29;281(39):28699-711. doi: 10.1074/jbc.M603609200. Epub 2006 Aug 1.
7
Lipid rafts: contentious only from simplistic standpoints.
Nat Rev Mol Cell Biol. 2006 Jun;7(6):456-62. doi: 10.1038/nrm1925.
8
The HIV lipidome: a raft with an unusual composition.
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2641-6. doi: 10.1073/pnas.0511136103. Epub 2006 Feb 15.
9
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay.
J Virol. 2005 Nov;79(22):14131-40. doi: 10.1128/JVI.79.22.14131-14140.2005.
10
Role of lipid rafts in virus replication.
Adv Virus Res. 2005;64:311-58. doi: 10.1016/S0065-3527(05)64010-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验